Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Nektar Therapeutics and AstraZeneca announced that the FDA has accepted its New Drug Application (NDA) for naloxegol, in opioid-induced constipation (OIC) for adult patients with chronic non-cancer pain. Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA).
RELATED: Gastrohepatic Disorders Resource Center
The NDA filing was based on data from the Phase 3 KODIAC program, consisting of four clinical trials designed to evaluate the safety and efficacy of naloxegol for the treatment of OIC. Two pivotal Phase 3 studies, KODIAC-04 (n=652) and KODIAC-05 (n=700), both 12-week, multicenter, randomized, double blind, placebo-controlled pivotal trials evaluated 12.5mg and 25mg doses of naloxegol, administered once-daily. KODIAC-07, a 12-week safety extension of KODIAC-04, and KODIAC-08 (n= 534) was an open-label controlled, randomized, 52-week, long-term safety trial.
Naloxegol may be the first once-daily oral peripherally acting mu-opioid receptor antagonist for patients with OIC. Naloxegol was developed using Nektar’s oral small molecule polymer conjugate technology.
For more information visit Nektar.com or AstraZeneca.com.
